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Background: Emergency surgery or transarterial embolization (TAE) are options for the 
treatment of recurrent or refractory nonvariceal upper gastrointestinal bleeding. Surgery has 
the disadvantage of high rates of postoperative morbidity and mortality. Embolization has 
become more available and has the advantage of avoiding laparotomy in this often unfit and 
elderly population.
Objective: To carry out a systematic review and meta-analysis of all studies that have directly 
compared TAE with emergency surgery in the treatment of major upper gastrointestinal bleeding 
that has failed therapeutic upper gastrointestinal endoscopy.
Methods: A literature search of Ovid MEDLINE, Embase, and Google Scholar was performed. 
The primary outcomes were all-cause mortality and rates of rebleeding. The secondary outcomes 
were length of stay and postoperative complications.
Results: A total of nine studies with 711 patients (347 who had embolization and 364 who had 
surgery) were analyzed. Patients in the TAE group were more likely to have ischemic heart 
disease (odds ratio [OR] =1.99; 95% confidence interval [CI]: 1.33, 2.98; P=0.0008; I2=67% 
[random effects model]) and be coagulopathic (pooled OR =2.23; 95% CI: 1.29, 3.87; P=0.004; 
I2=33% [fixed effects model]). Compared with TAE, surgery was associated with a lower risk 
of rebleeding (OR =0.41; 95% CI: 0.22, 0.77; P,0.0001; I2=55% [random effects]). There 
was no difference in mortality (OR =0.70; 95% CI: 0.48, 1.02; P=0.06; I2=44% [fixed effects]) 
between TAE and surgery.
Conclusion: When compared with surgery, TAE had a significant increased risk of rebleed-
ing rates after TAE; however, there were no differences in mortality rates. These findings are 
subject to multiple sources of bias due to poor quality studies. These findings support the need 
for a well-designed clinical trial to ascertain which technique is superior.
Keywords: meta-analysis, radiology, surgery, interventional radiology, GI hemmorhage 
Introduction
Nonvariceal upper gastrointestinal (GI) bleeding (NVUGB) is a common medical 
emergency requiring hospital admission. Improvements in endoscopic hemostatic 
techniques and medication have meant that only 13% of patients develop rebleeding.1 
Rebleeding is a significant predictor of risk for mortality and can often be salvaged by 
further therapeutic endoscopy.2 Consequently the requirement for emergency surgery 
has dropped from approximately 20% in the 1970s to less than 2% in the present day.1 
Patients who fail endoscopic hemostasis are often elderly with multiple comorbidities. 
Consequently these patients are at high risk for morbidity and mortality after emergency 
surgery. Mortality ranges from 10%−30% following operative management.1,3
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Although the technique of stopping bleeding from upper 
GI tract lesions with transarterial embolization (TAE) was first 
described in 1972,4 it has only recently become more available. 
Critics in the past have expressed concern about TAE being 
poorly available, especially out of routine work hours. How-
ever, a recent survey has shown good availability, principally 
in larger teaching hospitals.5 It is especially used in patients 
with multiple medical comorbidities who are poor candidates 
for surgery. Developments in interventional radiological equip-
ment and techniques, especially low-prolife catheter systems 
and advanced embolic agents, such as microcoils, chemical 
particles, and cyanoacrylate glues, have allowed embolization to 
have a high success rate in achieving hemostasis.6 The  principal 
advantage of interventional radiology is the avoidance of major 
emergency surgery in a critically ill and unstable patient.
The published guidelines for managing refractory 
NVUGB have evolved over time. The British Society of 
Gastroenterology guidance published in 2002 recommended 
that active NVUGB that cannot be stopped by endoscopic 
intervention needs an urgent surgical operation.7 The Scottish 
Intercollegiate Guidelines Network 2008 guidance8 suggests 
that NVUGB not controlled by endoscopy should be treated by 
repeat endoscopic treatment, selective arterial embolization, 
or surgery (grade D evidence).8 The International  Consensus 
Upper Gastrointestinal Bleeding Conference Group  published 
guidelines in 2010 recommending that patients with active 
NVUGB that cannot be stopped by  endoscopic intervention 
should be considered for  embolization therapy.9 The 2012 UK 
National Institute of Clinical Excellence (NICE) guidance rec-
ommends that unstable patients who rebleed after endoscopic 
treatment should be offered interventional radiology and that 
if this is not promptly available, the patient should be referred 
urgently for surgery.10 This latest NICE guidance is based on 
very low-quality evidence from observational studies and the 
recommendation of the guidelines development group.
Given the fact that all NVUGB guidance for severe and 
refractory bleeding relies on evidence of limited quality, high-
quality randomized trials are desperately required. However, 
these would be difficult logistically and are unlikely to be fea-
sible for a variety of reasons. Because of the paucity of trials, 
we decided to perform a systematic review and meta-analysis 
of the literature comparing TAE to emergency surgery.
Methods
Study identification
We searched Ovid MEDLINE (1946 to October 1, 2013), 
Embase (1980 to 2013 week 17), and Google Scholar. The 
medical subject headings (MeSH) search terms and keywords 
used were (“gastrointestinal bleeding” or “GI bleeding”) 
and (“embolization” or “embolization”) and “surgery”. The 
search was performed in May 2013. Lists of citations were 
reviewed independently by three authors (ADB, EAG, and 
MPD). Studies were retrieved, and relevant studies were 
identified via screening of their title and abstracts. The bib-
liographies of identified studies were hand searched, and any 
further relevant studies were included.
inclusion and exclusion criteria
Participants in studies had to be adults undergoing either 
TAE or surgery, for the treatment of NVUGB that had 
failed endoscopic management. Only studies (random-
ized controlled trial [RCT], prospective observational or 
 retrospective studies) that directly compared the two tech-
niques were considered for further evaluation. Excluded were 
case reports, letters, and reviews containing no original data. 
The studies were selected by two authors (ADB and EAG), 
and disagreements were resolved by consensus discussion. 
Abstracts of studies were reviewed for relevance by two 
reviewers (ADB and EAG), and nonrelevant studies were 
not included in the analysis. The full text of selected studies 
was then examined to check for relevance, and studies were 
discarded if they were not relevant. In case of disagreement, 
the whole paper was reviewed and a consensus decision 
reached (Figure 1 and Table 1).
Outcomes
The baseline characteristics of the groups (age, comorbid-
ity, and hemoglobin levels) were compared. The primary 
outcomes were rebleeding rates and all-cause mortality. 
The secondary outcomes were rates of medical postopera-
tive complications (pneumonia, myocardial infarction [MI], 
kidney injury, and stroke) and length of hospital stay.
Data extraction and quality assessment
Articles that met the criteria for inclusion underwent data 
extraction using a Microsoft®  Excel®  spreadsheet (version 
2010;  Microsoft Corporation, Redmond, WA, USA). The 
data extracted were as follows: study; authors; journal; year 
of publication; mortality; rebleeding; length of stay; rates 
of pneumonia, MI, stroke and renal failure; preprocedure 
hemoglobin; age; American Society of Anesthesiology 
(ASA) classification status; and comorbidities (ischemic 
heart disease, diabetes, renal disease, respiratory disease, 
coagulopathy). Data were imported into Review Man-
ager (RevMan) Version 5.2  (Nordic Cochrane Centre, 
Copenhagen, Denmark).
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The quality of all nonrandomized observational stud-
ies was assessed using the Newcastle–Ottawa Scale.11 This 
was assessed by examining three factors: method of patient 
selection, comparability of the study groups, and number of 
outcomes reported. Two reviewers independently allocated 
scores for study quality, and disagreement was resolved by re-
examining the relevant paper until consensus was achieved. 
The maximum score was nine stars, and high-quality studies 
usually had greater than seven stars.
statistical analysis
Measures of treatment effect were chosen pragmatically, 
based on the available literature and clinically relevant end 
points. The primary outcomes were overall mortality and 
rates of rebleeding. The secondary outcomes were ASA 
score, age of patient, length of stay, rates of  pneumonia/
MI/renal failure/stroke, age, preoperative hemoglobin 
 levels, and rates of preoperative ischemic heart disease/
renal  disease/respiratory disease/coagulopathy. All 
models were fixed- effects, unless significant statistical 
heterogeneity (.50% was noted), when a random effects 
model was used.  Statistical heterogeneity was determined 
using the I2 estimates, and was defined as low (,25%), 
moderate (25%−50%), and high (.50%).  Publication 
bias was assessed by funnel plots and the Egger Test (data 
was imported into Stata® 12 [version 12.1;  StataCorp LP, 
 College Station, TX, USA] to carry this out). A sensitivity 
analysis was carried out by taking studies out of each model 
sequentially, the largest study being removed first. All the 
statistical analyses were performed with Review Manager 
5.2 and Stata 12.1.
Results
This review was reported in accordance with the guidelines 
of the quality of reporting of meta-analyses (preferred 
reporting items for systematic reviews and meta-analyses 
[PRISMA])12 statement.
Study identification, selection  
and quality assessment:
In total, 432 studies were identified through database search-
ing, and three additional studies were found through other 
sources. After the removal of duplicates, 402 records were 
left for screening. Of these 402, nine studies were taken 
forward and 393 excluded from the analysis (Figure 1). 
In total, nine studies, with a total of 711 patients, were 
examined, with 347 patients in the TAE group and 364 in 
the surgery group. Assessment of the quality of the stud-
ies revealed that all the studies were adequate according 
to the Newcastle−Ottawa Scale (Table S1). They mainly 
comprised of retrospective cohort data, with no age, sex 
or comorbidity matching, due to the limitations of the type 
of study being undertaken. It could be argued that there 
was severe selection bias in these studies as patients with 
greater comorbidity were selected for TAE. Data complete-
ness was reasonable; however, comparability was poor 
because of the lack of selection of patients to standardize 
outcomes. No randomized studies were identified in our 
literature search.
Publication bias
Presence of publication bias was assessed separately 
for each outcome by visual inspection of funnel plots 
 (Figures S1 and S2) and the Egger test. In order to perform the 
Egger test, data were imported into Stata 12.1. No evidence 
of publication bias was identified.
432 records
identified through
database
searching
3 additional
records identified
through other
sources
402 records after duplicates
removed
402 records
screened
11 full-text
articles assessed
for eligibility
9 studies
included in
qualitative
synthesis
9 studies
included in
quantitative
synthesis
(meta-analysis)
391 records
excluded
2 full-text
articles excluded,
with reasons
Figure 1 Flowchart showing study selection.
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Embolization technique and surgical 
procedure performed
We summarized the characteristics of the included studies, 
which comprised a descriptive analysis of the techniques used 
for TAE and surgery (Table 1). There was no detail in the 
studies as to whether surgery was performed laparoscopically 
or as an “open” procedure. There were considerable differ-
ences in the techniques for embolization performed and the 
surgical procedures used. Some studies included all etiologies 
of upper GI bleeding, whilst others included only peptic ulcer 
disease or specifically, duodenal ulcers (Table 1).
Baseline differences
In order to ascertain whether there was any obvious selection 
bias between the groups, we compared a variety of baseline 
factors. The mean age difference (Figure 2) between the sur-
gery and embolization group was 3.60 years (95%  confidence 
interval [CI]: −0.90, 8.10; P=0.12; I2=73% [random effects 
model]), with a nonsignificant trend towards older age in 
the embolization group. When examining preoperative 
morbidity, only two studies contained data regarding ASA 
grade. Taking ASA .3 as a cutoff for “severe” morbidity, 
33/62 patients in the embolization group and 46/119 in the 
surgery group had ASA .3 (odds ratio [OR] =1.83; 95% 
CI: 0.35, 9.64; P=0.48; I2=85%, [random effects]). The two 
 studies with Acute Physiology and Chronic Health  Evaluation 
II (APACHE-II) score data were not analyzable as the data 
was in a different format and they could not be standardized. 
With regards to preoperative hemoglobin  (Figure 3), only five 
studies had analyzable data, with a mean difference of 0.26 
g/dL of hemoglobin (95% CI: −0.24, 0.76; P=0.31; I2=8% 
[fixed effects model]) between the surgery and embolization 
groups.
The preoperative comorbidities also underwent meta-
analysis (Table S2); there were significant differences in the 
prevalence of ischemic heart disease, with the angiography 
group being significantly more likely to have ischemic heart 
disease (OR =1.99; 95% CI: 1.33, 2.98; P=0.0008; I2=67% 
[random effects]). A similar picture was seen for patients 
with preexisting coagulopathy, with patients undergoing TAE 
significantly more likely to be coagulopathic (OR =2.23; 
95% CI: 1.29, 3.87: P=0.004; I2=33% [fixed effects]). 
Coagulopathy was defined as thrombocytopenia with plate-
let counts ,50,000/mm3 and/or a prothrombin time 50% of 
the coagulation activity of normal reference plasma, and/or an 
activated prothromboplastin time .50 seconds. As we were 
concerned that differences between the groups were due to 
TAE patients being coagulopathic, we carried out a random W
on
g,
 2
01
1
33
h
on
g 
K
on
g
20
00
−2
00
9
si
ng
le
 c
en
te
r,
 
re
tr
os
pe
ct
iv
e,
 
co
ho
rt
D
uo
de
na
l  
an
d 
ga
st
ri
c 
 
ul
ce
rs
32
56
Fi
be
re
d 
pl
at
in
um
 c
oi
l
U
lc
er
 p
la
ca
tio
n 
or
 e
xc
is
io
n 
(n
=3
8)
 
Pa
rt
ia
l g
as
tr
ec
to
m
y 
(n
=1
0)
 
V
ag
ot
om
y 
an
d 
ga
st
ro
je
ju
no
st
om
y 
or
 p
yl
or
op
la
st
y 
(n
=7
) 
T
ot
al
 g
as
tr
ec
to
m
y 
(n
=1
)
a
de
qu
at
e
A
bb
re
vi
at
io
ns
: G
D
a
, g
as
tr
od
uo
de
na
l a
rt
er
y;
 T
a
E,
 t
ra
ns
ar
te
ri
al
 e
m
bo
liz
at
io
n.
Clinical and Experimental Gastroenterology 2014:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
98
Beggs et al
Study or subgroup
Ang et al28
Eriksson et al16
Jairath et al13
Larssen et al30
Ripoll et al14
Wong et al32
Venclauskas et al31
66.5
76
66.5
80
75.2
69.6
73.1
15.6
10
17
18
10.9
16.1
12.3
30
40
60
36
31
24
32
68.2
71
71.2
73
63.3
61.9
71.1
15
12
14
15
14.5
14.1
14
63
51
97
10
39
50
56
14.1%
17.0%
16.2%
9.2%
15.1%
13.0%
15.5%
Total (95% Cl) 253 366 100.0%
Heterogeneity: τ2 =25.78; χ2 =22.00, df=6 (P=0.001); I2=73%
Test for overall effect: Z=1.57 (P=0.12)
−1.70 [−8.40, 5.00]
5.00 [0.48, 9.52]
−4.70 [−9.82, 0.42]
7.00 [−4.00, 18.00]
11.90 [5.95, 17.85]
7.70 [0.17, 15.23]
2.00 [−3.62, 7.62]
3.60 [−0.90, 8.10]
1000 50−50−100
Favors angiography Favors surgery
Embolization
Mean MeanSD SDTotal Total
Surgery
Weight
Mean difference
IV, random, 95% Cl
Mean difference
IV, random, 95% Cl
Figure 2 Forest plot of mean age, between the embolization and TaE groups.
Abbreviations: Ci, confidence interval; df, degrees of freedom; iV, initialization vector; sD, standard deviation; TaE, transarterial embolization.
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effects meta-regression using summary-level data (Stata 
12.1) of rebleeding rates and mortality, using coagulopathy as 
a covariate. No significant interaction between coagulopathy 
and mortality/rebleeding rates was seen (data not shown). 
There were no differences between the groups for diabetes, 
renal disease, or respiratory diseases.
Clinical outcomes
Primary outcomes
For mortality, there were 61 deaths in the angiography group 
and 101 in the surgery group (Figure 4), with no difference 
between the two groups in terms of mortality (OR =0.70; 
95% CI: 0.48, 1.02; P=0.06; I2=44% [fixed effects]). There 
was moderate between-study statistical heterogeneity, pos-
sibly because of the variable definition of mortality used in 
the studies. The Jairaith et al13 and Ripoll et al14 studies both 
quoted “in hospital” mortality rates; the remainder quoted 
30-day mortality rates. When the Jairath et al13 and Ripoll 
et al14 studies were considered together, excluding the other 
studies, there was no mortality difference between surgery 
and embolization (OR =2.32; 95% CI: 0.87, 6.16; P=0.899; 
I2=50% [random effects]).
For rebleeding rates, there were 78 events in the angio-
graphy group and 45 events in the surgery group (Figure 5), 
with surgery showing a reduced odds of rebleeding compared 
with TAE (OR =0.41; 95% CI: 0.22, 0.77; P=0.006, I2=53% 
[random effects]). Destinations for patients failing initial 
TAE therapy are shown in Table S3.
secondary outcomes
For length of stay, the mean difference between surgery 
and angiography was 0.75 days (95% CI: −2.36, 3.85 days; 
P=0.64; I2=56% [random effects]), nonsignificantly favor-
ing angiography; however, only seven studies out of the 
nine had data that was meta-analyzable for this variable 
(data not shown).
For other markers of postoperative morbidity, only 
two studies quoted rates of pneumonia, MI, renal failure, 
and stroke. In total, there were 92 complications in the 
 embolization group and 81 in the surgery group (OR =0.93; 
95% CI: 0.60, 1.40; P=0.72; I2=0% [fixed effects]). For pneu-
monia, there were 18 events in the angiography group and 34 
events in the surgery group (data not shown), but no overall 
effect for either intervention was seen (OR =1.07; 95% CI: 
0.25, 4.53; P=0.93; I2=77% [random effects]).
For MI, there were eleven events in the angiography 
group and 15 events in the surgery group, with no overall 
effect for either intervention (OR =1.54; 95% CI: 0.65, 
3.60; P=0.32; I2=0% [fixed effects]). For renal failure, there 
were nine events in the angiography group and 21 in the 
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surgery group, but no effect was seen for either  intervention 
(OR =0.78; 95% CI: 0.34, 1.81; P=0.56; I2=0% [fixed 
effects]). For stroke there were four events in the angiogra-
phy group and eleven in the surgery group, with no overall 
effect seen (OR =0.66; 95% CI: 0.20, 2.18; P=0.57; I2=0% 
[fixed effects]).
sensitivity analysis
A sensitivity analysis was performed separately for each 
outcome. Analyses for the primary outcomes, mortality and 
rebleeding rates, demonstrated no significant change to the 
overall estimate with sequential removal of studies, starting 
with the largest study.
In order to ascertain whether the age of the study had 
an impact on the rebleeding and mortality rates observed, 
the oldest studies (recruitment starting prior to 2000) were 
removed sequentially. For mortality rates, sequential and 
simultaneous removal of Defreyne et al,15 Eriksson et al,16 
and Ripoll et al14 had no effect on mortality rates. Separate 
sequential removal of Jairaith et al13 and then Ripoll et al14 
also did not affect the mortality rate. For rebleeding rates, 
sequential removal of Defreyne et al,15 Eriksson et al,16 
and Ripoll et al14 had no effect on rebleeding rates, but 
simultaneous removal of all three studies rendered the 
rates of rebleeding nonsignificant (OR =0.55; 95% CI: 
0.23, 1.33; P=0.09; I2=50% [random effects]), although 
there was still a trend towards reduced rebleeding after 
surgery.
For the secondary outcomes, length of stay, compli-
cations (pneumonia, MI, stroke, and renal failure), and 
preprocedure hemoglobin, there was also no significant 
change with the sequential removal of studies. Sensitivity 
analysis for age and coagulopathy demonstrated significant 
changes in the combined effect size with removal of stud-
ies. For age, removal of Jairath et al13 led to a significant 
difference in age (mean difference =5.16 years; 95% CI: 
1.30, 9.02 days; P=0.009; I2=52% [random effects]). For 
coagulopathy, removal of Jairath et al13 led to overall 
nonsignificance (OR =2.06; 95% CI: 0.94, 4.50; P=0.07; 
I2=65% [random effects]).
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Figure 4 Forest plot of rates of mortality, comparing TaE versus surgery.
Abbreviations: Ci, confidence interval; df, degrees of freedom; M-h, Mantel-haenszel; TaE, transarterial embolization.
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Figure 5 Forest plot of rates of rebleeding after therapy, comparing TaE versus surgery.
Abbreviations: Ci, confidence interval; df, degrees of freedom; M-h, Mantel-haenszel; TaE, transarterial embolization.
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Conclusion
TAE has been increasingly adopted as a treatment for 
NVUGB that has failed initial endoscopic management, 
particularly in elderly and frail patients. Although TAE is 
typically chosen in older patients who have high operative 
risk (medical comorbidities or older age), our meta-analysis 
found a nonsignificant trend towards older patients. The only 
other baseline statistically significant differences seen in 
patients with TAE were in the frequency of ischemic heart 
disease and coagulopathy, which were higher in the TAE 
group. This undoubtedly reflects the preference of the treating 
clinicians to avoid emergency surgery in patients with severe 
ischemic heart disease. This was undoubtedly a significant 
potential source of bias in this study as it is possible that 
patients enrolled into the TAE arm of the study may have 
been selected on the basis of their significant comorbidity. 
In the absence of patient-level data, it is impossible to gauge 
the effects of the morbidity of individual patients across the 
studies. Also, patients with coagulopathy who either had 
a significant bleeding episode or who were on oral antico-
agulation for medical reasons could also be a source of bias 
as these patients may have preferentially undergone TAE 
rather than surgery. There is no clear evidence to support 
or refute this hypothesis in the studies analyzed here. None 
of the studies included had data available to understand 
the decision- making process involved in selecting each 
 intervention. Another important factor is the age of the 
studies in this meta-analysis. The earliest of these studies 
recruited patients from 1986, and both endoscopic and sur-
gical practice have changed markedly since this point, and 
this will inevitably lead to bias. In our sensitivity analysis, 
there was no difference in mortality by removing the oldest 
studies. The differences in rebleeding rates seen between 
surgery and TAE disappeared when the three oldest studies 
were removed; however, the trend towards lower rebleeding 
rates following surgery remained. Of note are the differing 
durations of embolization vs surgery in terms of operative 
time. The time taken to arrest hemorrhage would undoubtedly 
affect outcomes, although this was not measured in any of 
the studies examined.
We found higher rates of rebleeding in the group treated 
with TAE. There are several possible explanations for this. 
One strong factor is the rich collateral blood supply of the 
gastroduodenal artery, which includes blood supply from 
other vessels, including the pancreaticoduodenal and supe-
rior mesenteric artery branches, and gastroepiploic vessels. 
This means that coiling of the gastroduodenal artery from 
the coeliac axis alone may be inadequate to control duodenal 
ulcer bleeding as the gastroduodenal artery can then be back 
filled from other collateral branches of the superior mesen-
teric artery. It is also possible that the local vasoconstriction 
occurring in critically ill and hypovolemic patients leads 
to the appearance of cessation of bleeding during TAE but 
that following volume restoration, rebleeding occurs as the 
vessel expands to normal size and the embolized coils no 
longer “fit.”17
Another explanation could be related to the baseline 
difference we found in the rates of coagulopathy between 
the two groups. The embolization group had a higher rate 
of coagulopathy, which has been shown to be associated 
with an OR of hemostatic failure of between 2.9 and 19.6 
in some studies.18−20 There was no data describing how 
coagulopathy was treated in any of the studies. However, 
meta-regression of the available data did not demonstrate 
a significant interaction between coagulopathy and rates of 
rebleeding. We acknowledge that our meta-regression was 
underpowered, featuring only eight studies, which makes 
the evidence for this inconclusive. Previous studies have 
suggested that the earlier hemorrhage is controlled, the less 
need for large-volume blood transfusion with its associated 
coagulopathy, and subsequent organ failure and poor outcome 
are potentially avoided.21
Complications of TAE appeared to be underreported in 
the studies we analyzed, with none of the studies reporting 
any ischemic complications. Although the upper GI tract 
usually has a rich collateral blood supply, other studies have 
shown ischemic complications to occur in between 7% and 
16% of cases.22,23 These can either present acutely, with GI 
necrosis, or later, with ischemic duodenal stenosis. Other 
reported complications of TAE include access site arterial 
trauma, such as intimal dissection or pseudoaneurysm for-
mation, contrast-induced nephropathy, and embolization of 
nontarget vessels.
We found no differences in the mortality between the 
embolization and surgery groups, despite higher rates of 
rebleeding in the embolization group. We accept there are 
baseline differences in the groups and that there may have 
been a selection bias towards entering patients with more 
comorbidities into the TAE group. The evidence regarding 
comorbidities in these studies is limited; however, there was 
no clear evidence that there was increased comorbidity in the 
TAE group. It is possible that the increased rates of rebleed-
ing seen in the TAE group were due to the increased frailty of 
these patients, leading to higher rebleeding rates. Causes of 
mortality after upper GI bleeding are complex. Sung et al24 
recently analyzed causes of mortality in 10,428 patients 
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who were admitted with peptic ulcer bleeding. They found 
a 6% 30-day mortality rate, and 80% of patients died from 
severe comorbid diseases and not the failure to control 
hemorrhage. In contrast in a recent population-based study, 
mortality from all causes was increased compared with 
matched controls.25 Less than half of this risk of excess 
mortality was related to comorbidity, such as malignancy 
or cardiovascular disease.
Although this is the largest series that has directly 
compared the use of surgery or TAE in major upper GI 
hemorrhage, our results are based on nonrandomized 
studies of variable quality. Therefore, there are several 
limitations to our results, caused by potential selection 
bias, confounding variables, and lack of blinding. A par-
ticular weakness is that multiple surgical and radiological 
techniques, spanning over 25 years of practice, feature in 
these studies, and this will inevitably cause a degree of 
heterogeneity of outcome. In the absence of high-quality 
evidence, our study indicates that there is no difference 
in mortality between surgery and embolization. This is 
severely confounded by the selection bias inherent to 
these types of nonrandomized studies. The increased risk 
of rebleeding in patients undergoing TAE in this study is 
probably related to selection bias as well as the inclusion 
of older studies that were conducted at the time when the 
technique was in its infancy. We are also concerned about 
the potential risks of postprocedural ischemic complica-
tions. Further research in this area, using standardized 
interventional radiological techniques and equipment, is 
clearly needed.
A randomized study comparing TAE and surgery in 
peptic ulcer bleeding uncontrolled by endoscopy is cur-
rently recruiting patients in Hong Kong (ClinicalTrials.gov: 
NCT00766961).26 Its primary outcome is 30-day  mortality, 
and the secondary outcomes are recurrent bleeding, need 
for further intervention in terms of either surgery or inter-
ventional radiology, and postprocedural  complications. 
However, the trial was registered in 2007 and has yet to 
recruit its target of 184 patients. This could be in part 
related to problems gaining consent in the emergency situ-
ation. Recruitment has been slow (personal communica-
tion with study primary investigator), and two other major 
centers that can offer both treatments are now involved. 
The possibilities for expanding recruitment to other major 
centers are limited because there are few hospitals that have 
rapid access to appropriately experienced interventional 
radiologists and surgeons who are immediately available 
to stem refractory hemorrhage. For a RCT to be a success, 
the interventional suite and the operating theatre would 
have to be in very close proximity or a multiuse facility 
developed.
The technological advances in the management of hem-
orrhage via interventional radiology are improving rapidly, 
whilst the experience of surgeons in the management of upper 
GI hemorrhage is dwindling. Over the past few decades the 
number of patients requiring surgical intervention for upper 
GI bleeding has decreased enormously. In the 1990s, up to 
13% of patients required surgery to control bleeding from 
peptic ulcer disease.27 However, with improved endoscopic 
hemostatic techniques (such as heater probe, large volumes 
of adrenaline injection, and clip application) and intravenous 
proton pump infusions, the rate of surgical procedures has 
dropped to less than 2% in the present day.1,28
Until RCT evidence is available, there is no clear evidence 
to recommend TAE over surgery, and this should be consid-
ered as an option in selected cases only, such as for patients 
unfit for emergency surgery or where specialist surgical 
skills are lacking. TAE should not be seen as the only first-
line option, and surgery is still a valid option for refractory 
NVUGB that has failed endoscopic management.
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Table S1 newcastle−Ottawa quality assessment scale table
Study Selection  
(out of 4)
Comparability  
(out of 2)
Outcome  
(out of 3)
Total  
(out of 9)
Overall  
rating
ang et al1 3 0 2 5 adequate
Defreyne et al2 3 0 2 5 adequate
Eriksson et al3 3 0 2 5 adequate
Jairath et al4 3 0 2 5 adequate
langner et al5 3 0 1 4 adequate
larssen et al6 3 0 2 5 adequate
ripoll et al7 3 0 2 5 adequate
Venclauskas et al8 3 0 2 5 adequate
Wong et al9 3 0 2 5 adequate
SE(log[OR])0
0.5
1
1.5
2
0.01 0.1 1 10 100
Eriksson et al3
Langner et al5
Larssen et al6
Venclauskas et al8
Wong et al9
Defreyne et al2
Jairath et al4
Ang et al1
Ripoll et al7
OR
Figure S1 Funnel plot of mortality rates in studies analyzed.
Abbreviations: Or, odds ratio; sE, standard error.
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Figure S2 Funnel plot of rebleeding rates in studies analyzed.
Abbreviations: Or, odds ratio; sE, standard error.
Table S2 Table of meta-analyzed preprocedure comorbidities
Comorbidity Number  
studies
OR 95% CI P-value I2 Heterogeneity
ischemic heart disease 6 1.99 1.33, 2.98 0.0008 67% high
Diabetes 4 1.19 0.66, 2.15 0.56 38% Moderate
renal disease 6 1.86 0.98, 3.53 0.06 0% low
respiratory disease 6 1.31 0.81, 2.12 0.28 0% low
Coagulopathy 3 2.23 1.29, 3.87 0.004 33% Moderate
Abbreviations: CI, confidence interval; OR, odds ratio.
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Table S3 Therapy for rebleeding after initial TaE or surgery
Study Initial failures Repeat TAE Endoscopy Surgery Not done
TAE  
(n/total)
Surgery 
(n/total)
TAE 
(n/total)
Surgery 
(n/total)
TAE  
(n/total)
Surgery  
(n/total)
TAE  
(n/total)
Surgery 
(n/total)
TAE  
(n/total)
Surgery 
(n/total)
ang et al1 14/30 (46.7%) 8/63 (12.6%) 7* 4 4 – 3 1 3 3
Defreyne et al2 20/46 (43.5%) 13/51 (25.5%) – 1 5 8 15 3 – –
Eriksson et al3 10/40 (25.0%) 9/51 (17.6%) 5 8 – – 5 1 – –
Jairath et al4 6/97 (6.2%) – – – – – 6 – – –
langner et al5 3/11 (27.3%) 2/12 (16.7%) – 1 1 1 2 – – –
larssen et al6 3/36 (8.3%) 2/10 (20.0%)** – ? – ? 3 ? – ?
ripoll et al7 9/31 (29.0%) 9/39 (23.1%) – – – – 5 9 4 –
Venclauskas et al8 3/24 (12.5%) 4/50 (8.0%) – – 1 1 2 3 – –
Wong et al9 11/32 (34.4%) 7/56 (12.5%) – 4 8 2 3 1 – –
Notes: *Of these seven in ang et al: only one patient was successfully embolized; two patients underwent repeat endoscopy; two underwent repeat TaE with 
success, and two underwent surgical intervention; **of these two patients, it was not specified in the paper what therapy they received for rebleeding after surgery. 
Abbreviation: TaE, transarterial embolization.
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